drugset / Trial / NCT03766269

Dronabinol Opioid Sparing Evaluation (DOSE) Trial

NCT03766269

Phase 2 Unknown 280 enrolled Daisy Pharma Opioid Venture, LLC
NaSingle-groupOpen-labelTreatment

Summary

This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients for their chronic pain condition. The purpose of this trial will be to assess the effectiveness of Dronabinol when combined with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of opioid-related side effects. Participants will take the study-drug, Dronabinol, along with their regular prescribed opioids and the results will be evaluated and analyzed according to defined endpoints.

Timeline

Start
2018-12-01
Primary completion
2019-06-01
Completion
2019-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 20 mg

Indications